Four, although the combination therapy including GLP-1 receptor agonists appears promising, it is important to note that most GLP-1 RA trials except for FLOW trial26 were conducted in populations with obesity, often using high doses. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.